Lumi-Solve

-

  • Nearly 250 million people worldwide are affected by peripheral arterial disease

  • Between 40-70% of narrowed arteries treated with plain balloon angioplasty require repeat surgery after 12 months

Developed by a multidisciplinary team, Lumi-Solve is an early-phase biomedical device for the treatment of restenosis in Peripheral Artery Disease (PAD). Lumi-Solve enables safer and more precise delivery of medication to affected blood vessels, using a breakthrough light-activated drug-eluting balloon (DEB) catheter technology.

Contact us and get involved or find out more about Lumi-Solve.

Animation-crop

About us

In conjunction with our national and International collaborators, Monash University’s revolutionary biomedical device Lumi-Solve is focused on safer endovascular drug delivery for the treatment of PAD-associated post-angioplasty restenosis utilizing a novel UV light-activated epigenetic drug strategy and Swiss fibre-optic technology.

Currently available for evaluation in large animal models and early-phase human studies.

What is Peripheral Arterial Disease (PAD)?

Find out more about Peripheral Arterial Disease (PAD) and its impact on patients.

Lumi-Solve technology

Lumi-Solve represents a first-in-class photo-activated DEB device, and is an innovative advance in the evolution of angioplasty therapy.

Research papers and news media

Explore our research publication highlights and media engagements.